Advertisement

Topics

Merck Eprova AG Company Profile

05:40 EDT 21st September 2018 | BioPortfolio

Eprova has modern laboratories; we always keep equipment and infrastructure for chemical synthesis, production and analysis up to the current standards in technology. As a matter of course we also place high demands on safety and environmental protection. To us quality is not just another catchword. It is our commitment. Co-ordinated by our Quality-Assurance team, we serve you with top quality according to cGMP rules. Eprova is regularly inspected and has the relevant official authorisations. Our greatest challenge is to keep constantly abreast of current knowledge. For this reason, we attach great importance to our training. Our employees are all highly qualified and highly motivated to carry out your orders to your upmost satisfaction. In overlapping matters, our Microdepartments co-operate very closely. Experts from "Synthesis and Development", "Analytics", "Biology/Biochemistry", "Product Manufacturing", "Literature/Patents", "Quality Assurance" and "Safety/Environment" complement each other optimally. This close internal network is the guarantee for the comprehensive and interdisciplinary realisation of your project. We offer you a prompt and unbureaucratic but, at the same time, sound and reliable execution of your orders. Working with Eprova means for you that you no longer have to plan for a peak capacity.

Location

Im latermencker 5
Scharrhausen
CH-8200
Switzerland

Contact

Phone: 41(52)630 72 72
Fax: 41(52)630 72 55
Email: info@eprova.com


News Articles [972 Associated News Articles listed on BioPortfolio]

Merck Ventures: Success in funding early innovation

Merck Ventures is the strategic, corporate venture capital arm of Merck. Its mandate is to invest in innovative technologies and products with the potential to significantly impact Merck‘s core busi...

Merck: Verkauf wird positiv aufgenommen

Die Analysten von Independent Research bestätigen die Halteempfehlung für die Aktien von Merck. Das Kursziel für die Papiere von Merck sehen die Experten weiter bei 88,00 Euro. Die jüngsten Entwic...

MERCK IM FOKUS: Ein Jubiläumsjahr in Darmstadt zwischen Hoffen und Bangen

FRANKFURT (dpa-AFX Broker) - Wie ist die Lage bei Merck? Die wichtigsten Punkte für das Unternehmen, was die Experten sagen und wie es für die Aktie läuft: DAS IST LOS BEI MERCK Aus einer altehrwü...

Merck posts strong first-quarter profit, but revenue light

In this Dec. 18, 2014, file photo, a person walks through a Merck company building, in Kenilworth, N.J. Merck & Co. reports earnings Tuesday, May 1, 2018.

Merck & Co will Medikamentenpreise senken

FRANKFURT (Dow Jones)--Der US-Pharmakonzern Merck & Co will die Preise für einige Medikamente senken. Merck teilte am Donnerstag mit, dass sie "den Patienten helfen will, die Kosten aus der eigene...

IO Biotech studies NSCLC combo treatment with Merck

IO Biotech ApS and Merck &Co. Inc. will together conduct a Phase I/II trial studying the combination of IO’s investigational IO102 with Merck’s Keytruda (pembrolizumab) for metastatic non-small ce...

Call auf Merck: Ausbruch gelungen!

1668 als Apotheke gegründet, ist die in Darmstadt beheimatete Merck AG heute als Pharma- und Chemiekonzern international aktiv. Mit einer 350-jährigen Firmengeschichte sieht sich Merck heute als ei....

Merck Teams With Moderna To Take On One Of The Toughest Targets In Cancer

Merck is making a $125 million investment in Moderna as part of a new funding round. "We're encourage by the potential for RNA-based vaccines," says Eric Rubin, a Merck vice president.

PubMed Articles [16 Associated PubMed Articles listed on BioPortfolio]

Winners of the Emanuel Merck Lectureship and the Heinrich Emanuel Merck Award.

Treating MS without continuous immunosuppression: an interview with Luciano Rossetti.

Luciano Rossetti, MD, Executive Vice President, Global Head of R&D at Merck KGaA, Darmstadt, Germany speaks to Laura Dormer, Commissioning Editor Luciano Rossetti, MD, is Executive Vice President, Glo...

Merck vaccine heads Ebola countermeasures.

Japan Prize / Merck-Banyu Lectureship for Naoya Kumagai / DECHEMA Prize for Timothy Noël.

The Recipe for Corporate Longevity: From the Perspective of "Managing Innovation".

The elephant is in the room-a metaphorical idiom for an obvious problem or risk that nobody wants to discuss. This abstract is not intended to be a summary, to reveal major findings, or unveil conclus...

Clinical Trials [86 Associated Clinical Trials listed on BioPortfolio]

Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' Measles, Mumps and Rubella (MMR) Vaccine (209762) Compared to Merck & Co., Inc.'s MMR Vaccine in Healthy Children 12 to 15 Months of Age

The purpose of this study is to evaluate the immunogenicity and safety of GSK Biologicals' trivalent MMR (Priorix®), comparing it to Merck's MMR vaccine (M-M-R®II), which is approved for...

Study of EMD531444 in Subjects With Stage III Unresectable Non-small Cell Lung Cancer (NSCLC) Following Primary Chemoradiotherapy

Darmstadt, Germany, June 17 2010 - Merck Serono, a division of Merck KGaA, and its U.S. affiliate, EMD Serono, Inc. today announced that they are resuming their Stimuvax® (BLP25 liposome ...

Immunogenicity and Safety of Kinrix + MMR With and Without Varicella Vaccine in Healthy Children 4-6 Years

The purpose of the study is to evaluate the immunogenicity and safety of Kinrix when co-administered with varicella (Varivax® [varicella virus vaccine live], Merck and Company) and MMR va...

Glucophage Extended Release (GXR) China Bioequivalence Study (Nantong - Darmstadt)

The study will assess the bioequivalence between single doses of GXR manufactured in Merck Nantong China (test drug) and GXR manufactured in Merck Darmstadt Germany (reference drug) under ...

Glucophage® Extended Release (XR) 750 Milligram (mg) Indonesia Bioequivalence (BE) Study

The purpose of this study is to assess bioequivalence between metformin hydrochloride (Glucophage® XR) manufactured in PT Merck Tbk, Indonesia (test drug) and metformin hydrochloride (Glu...

Companies [137 Associated Companies listed on BioPortfolio]

Merck Eprova AG

Eprova has modern laboratories; we always keep equipment and infrastructure for chemical synthesis, production and analysis up to the current standards in technology. As a matter of course we also pla...

Merck Foundation

The Merck Foundation is a U.S.-based, private charitable foundation. Established in 1957 by Merck, a global health care leader, the Foundation is funded entirely by the company an...

The Merck Foundation

The Merck Foundation is a U.S.-based, private charitable foundation. Established in 1957 by Merck, a global health care leader, the Foundation is funded entirely by the company an...

Merck & Co

Here you will find an overview of our activities in the core businesses of pharmaceuticals and chemicals. We illustrate the structure of our company. We present the Executive Board of Merck KGaA. ...

Merck Animal Health

Today's Merck is a global healthcare leader working to help the world be well. Merck Animal Health, known as MSD Animal Health outside the United States and Canada, is the global ...

More Information about "Merck Eprova AG" on BioPortfolio

We have published hundreds of Merck Eprova AG news stories on BioPortfolio along with dozens of Merck Eprova AG Clinical Trials and PubMed Articles about Merck Eprova AG for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Merck Eprova AG Companies in our database. You can also find out about relevant Merck Eprova AG Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks



Searches Linking to this Company Record